NZ721780A - Heterocyclic modulators of lipid synthesis for use against cancer and viral infections - Google Patents
Heterocyclic modulators of lipid synthesis for use against cancer and viral infectionsInfo
- Publication number
- NZ721780A NZ721780A NZ721780A NZ72178015A NZ721780A NZ 721780 A NZ721780 A NZ 721780A NZ 721780 A NZ721780 A NZ 721780A NZ 72178015 A NZ72178015 A NZ 72178015A NZ 721780 A NZ721780 A NZ 721780A
- Authority
- NZ
- New Zealand
- Prior art keywords
- lipid synthesis
- viral infections
- against cancer
- use against
- heterocyclic modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461924520P | 2014-01-07 | 2014-01-07 | |
| PCT/US2015/010459 WO2015105860A1 (en) | 2014-01-07 | 2015-01-07 | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ721780A true NZ721780A (en) | 2022-01-28 |
Family
ID=52394405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ721780A NZ721780A (en) | 2014-01-07 | 2015-01-07 | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9994550B2 (enExample) |
| EP (1) | EP3092232B1 (enExample) |
| JP (1) | JP6522007B2 (enExample) |
| KR (1) | KR102335142B1 (enExample) |
| CN (1) | CN105980376B (enExample) |
| AU (1) | AU2015204907B2 (enExample) |
| BR (1) | BR112016015879B1 (enExample) |
| CA (1) | CA2935767C (enExample) |
| ES (1) | ES2913858T3 (enExample) |
| IL (1) | IL246463B (enExample) |
| MX (1) | MX384392B (enExample) |
| NZ (1) | NZ721780A (enExample) |
| RU (1) | RU2766087C2 (enExample) |
| SG (1) | SG11201605422TA (enExample) |
| WO (1) | WO2015105860A1 (enExample) |
| ZA (1) | ZA201604560B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| KR102071095B1 (ko) * | 2012-07-03 | 2020-01-29 | 3-브이 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절인자 |
| ES2833454T3 (es) | 2014-08-15 | 2021-06-15 | Sagimet Biosciences Inc | Inhibidor de la ácido graso sintasa para su uso en el tratamiento de un cáncer farmacorresistente |
| CN105181844A (zh) * | 2015-09-11 | 2015-12-23 | 江苏嘉逸医药有限公司 | 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法 |
| KR102644934B1 (ko) * | 2016-11-11 | 2024-03-08 | 새지메트 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절인자 |
| WO2018111890A1 (en) * | 2016-12-12 | 2018-06-21 | Genentech, Inc. | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens |
| CN106562961B (zh) * | 2016-12-12 | 2017-09-01 | 深圳市宏辉浩医药科技有限公司 | 一种治疗脑梗塞的药物组合物 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2025086054A1 (zh) * | 2023-10-23 | 2025-05-01 | 歌礼生物科技（杭州）有限公司 | 一种包含苯甲腈衍生物的药物组合物 |
| AU2024395542A1 (en) | 2023-12-07 | 2026-05-28 | Böse Pharmaceuticals Ab | Sulfonamide derivatives and use thereof in the treatment of cryptosporidium infections |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| DE69418699T2 (de) | 1993-01-11 | 1999-09-30 | Dana-Farber Cancer Institute, Boston | Induktion der antworten zytotoxischer t-lymphozyten |
| RU2419612C2 (ru) * | 2003-12-23 | 2011-05-27 | Астекс Терапьютикс Лимитед | Производные пиразола в качестве модуляторов протеинкиназы |
| WO2008075077A1 (en) | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Piperidine derivatives for the treatment of obesity |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| TW200831092A (en) | 2006-12-21 | 2008-08-01 | Astrazeneca Ab | Therapeutic agents |
| LT2683244T (lt) * | 2011-03-08 | 2017-04-10 | 3-V Biosciences, Inc. | Lipidų sintezės heterocikliniai moduliatoriai |
| TWI522348B (zh) * | 2011-03-08 | 2016-02-21 | ３ Ｖ生物科技公司 | 脂質合成之雜環調節劑 |
| KR102071095B1 (ko) | 2012-07-03 | 2020-01-29 | 3-브이 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절인자 |
-
2015
- 2015-01-07 JP JP2016562737A patent/JP6522007B2/ja active Active
- 2015-01-07 EP EP15700939.0A patent/EP3092232B1/en active Active
- 2015-01-07 RU RU2016127634A patent/RU2766087C2/ru active
- 2015-01-07 WO PCT/US2015/010459 patent/WO2015105860A1/en not_active Ceased
- 2015-01-07 CA CA2935767A patent/CA2935767C/en active Active
- 2015-01-07 AU AU2015204907A patent/AU2015204907B2/en active Active
- 2015-01-07 CN CN201580003786.5A patent/CN105980376B/zh active Active
- 2015-01-07 KR KR1020167018178A patent/KR102335142B1/ko active Active
- 2015-01-07 ES ES15700939T patent/ES2913858T3/es active Active
- 2015-01-07 NZ NZ721780A patent/NZ721780A/en unknown
- 2015-01-07 SG SG11201605422TA patent/SG11201605422TA/en unknown
- 2015-01-07 MX MX2016008841A patent/MX384392B/es unknown
- 2015-01-07 BR BR112016015879-2A patent/BR112016015879B1/pt active IP Right Grant
- 2015-01-07 US US15/110,154 patent/US9994550B2/en active Active
-
2016
- 2016-06-26 IL IL246463A patent/IL246463B/en unknown
- 2016-07-05 ZA ZA2016/04560A patent/ZA201604560B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL246463A0 (en) | 2016-08-31 |
| SG11201605422TA (en) | 2016-07-28 |
| IL246463B (en) | 2022-04-01 |
| CA2935767A1 (en) | 2015-07-16 |
| RU2016127634A3 (enExample) | 2019-06-17 |
| CA2935767C (en) | 2023-01-31 |
| CN105980376B (zh) | 2019-03-22 |
| KR20160105416A (ko) | 2016-09-06 |
| US9994550B2 (en) | 2018-06-12 |
| WO2015105860A1 (en) | 2015-07-16 |
| US20160326141A1 (en) | 2016-11-10 |
| WO2015105860A9 (en) | 2016-02-04 |
| AU2015204907A1 (en) | 2016-07-21 |
| RU2766087C2 (ru) | 2022-02-07 |
| JP2017502083A (ja) | 2017-01-19 |
| CN105980376A (zh) | 2016-09-28 |
| RU2016127634A (ru) | 2018-02-09 |
| EP3092232B1 (en) | 2022-03-09 |
| AU2015204907B2 (en) | 2018-08-02 |
| KR102335142B1 (ko) | 2021-12-06 |
| EP3092232A1 (en) | 2016-11-16 |
| JP6522007B2 (ja) | 2019-05-29 |
| MX384392B (es) | 2025-03-14 |
| MX2016008841A (es) | 2016-10-13 |
| BR112016015879B1 (pt) | 2022-06-14 |
| ZA201604560B (en) | 2019-01-30 |
| BR112016015879A2 (enExample) | 2017-08-08 |
| ES2913858T3 (es) | 2022-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500591B1 (en) | Heterocyclic compounds and uses thereof | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| NZ703162A (en) | Heterocyclic modulators of lipid synthesis | |
| TW201613911A (en) | Heterocyclic compounds and uses thereof | |
| MX384392B (es) | Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| IN2014MN02598A (enExample) | ||
| TW201613864A (en) | Novel compounds | |
| EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
| PH12017501280B1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
| PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
| IN2013MU03308A (enExample) | ||
| IN2013CH04314A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2024 BY COMPUTER PACKAGES INC Effective date: 20221217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2025 BY COMPUTER PACKAGES INC Effective date: 20231217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2026 BY COMPUTER PACKAGES INC Effective date: 20241217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2027 BY COMPUTER PACKAGES INC Effective date: 20251217 |